A standing platform for cancer drug development using ctDNA-based evidence of recurrence.

The time required to conduct clinical trials limits the rate at which we can evaluate and deliver new treatment options to patients with cancer. New approaches to increase trial efficiency while maintaining rigor would benefit patients, especially in oncology, in which adjuvant trials hold promise for intercepting metastatic disease, but typically require large numbers of patients and many years to complete. We envision a standing platform - an infrastructure to support ongoing identification and trial enrolment of patients with cancer with early molecular evidence of disease (MED) after curative-intent therapy for early-stage cancer, based on the presence of circulating tumour DNA.

CDK4/6 Inhibitor Efficacy in -Mutant Metastatic Breast Cancer.

Background: In estrogen receptor-positive metastatic breast cancer, mutations (ESR1) are a common mechanism of acquired resistance to aromatase inhibitors (ArIh). However, the impact alterations have on CDK4/6 inhibitor (CDK4/6i) sensitivity has not been established. Analyses of CDK4/6i trials suggest that the endocrine therapy partner and specific allele may affect susceptibility.

Data visualization explorer: A tool for participant representation in pivotal trials of FDA-approved medicinal products.

This paper presents a 2015-2021 US Food and Drug Administration (FDA) Drug Trials Snapshots (DTS) Data Visualization Explorer-an interactive data visualization web-based tool (https://arielcarmeli.shinyapps.io/fda-drug-trial-snapshots-data-explorer) built in R and based on publicly available FDA clinical trial participation data and disease incidence data from the National Cancer Institute and Centers for Disease Control and Prevention.

The case for philanthropic investment to increase colorectal cancer screening rates: A novel paradigm to address a public health challenge.

Background: Colorectal cancer (CRC) remains a leading cause of cancer-related death despite being highly preventable. Efforts to increase participation in CRC screening have not met national goals. We developed a novel approach: building a business case for philanthropic investment in CRC screening.